Skip to main content
OpenTrials
Completed

NCT Number: NCT01164332

Sensitivity of Alternative NRL972 Detection Methods in Healthy Subjects

The disposition of NRL972 after a 15-second intravenous injection of 2 mg NRL972 is distinctly slower in patients with hepatic cirrhosis and acute hepatitis than in healthy control subjects. NRL972 appears to be a suitable investigational marker of hepatic transporter clearance dysfunction.

Although the pharmacokinetics of NRL972 provide a reliable differentiation between subject groups, this approach relies on precisely timed sampling of venous blood, cautious preparation, handling and on-site storage of plasma samples, the transfer of samples to a central laboratory for analysis, and the availability of a validated assay procedure.

For these reasons, there is interest in developing and validating alternative methods for determining the concentration of NRL972 in venous blood. Two such methods have been developed to date, but their utility in determining NRL972 pharmacokinetics has yet to be established.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cirrhosis Fibrosis Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

20 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Phase I-II study clinical of the Drug Research Center Ltd.

Balatonfüred, H-8230, Hungary

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subjects meeting the following conditions will be eligible for enrolment:

  • Males or females (females of non-childbearing potential or of childbearing potential while taking medically appropriate contraception)
  • Caucasian
  • Age: 20 to 45 years
  • BMI 20 - 26 kg.m-2
  • Healthy based on the pre-study examination
  • Suitable veins for easy cannulation
  • Willing and able to provide informed consent

Exclusion criteria

Subjects of any of the following categories will be excluded from enrolment:

General - all subjects

  • Previous participation in the trial
  • Participant in any other trial during the last 90 days
  • Donation of blood during the last 60 days or a history of blood loss exceeding 300 mL within the last 3 months
  • History of any clinically relevant allergy
  • Presence of any acute or chronic infection
  • Presence or history of any relevant co-morbidity
  • Resting systolic blood pressure > 160 or < 90 mmHg, diastolic blood pressure > 95 or < 50 mmHg
  • Clinically relevant ECG-abnormalities, prolonged QTc with > 450 msec in males and > 460 msec in females in particular
  • Presence of any relevant abnormality in the laboratory safety tests, especially low haemoglobin, increased liver enzymes
  • Positive serology for HBsAg, anti HBc and anti HCV
  • Positive HIV test
  • Positive alcohol or urine drug test on recruitment
  • History of alcohol and/or drug abuse and/or daily use of > 30 g alcohol
  • Smoking more than 10 cigarettes/day or equivalent of other tobacco products
  • Use of prohibited medication
  • Suspicion or evidence that the subject is not trustworthy and reliable
  • Suspicion or evidence that the subject is not able to make a free consent or to understand the information in this regard

General - all females

  • Positive pregnancy test
  • Lactating
  • Not using appropriate contraception in premenopausal women

Treatment and study plan

NRL972

Other

Two-hour intravenous infusion of 5 and 15 mg per hour

Primary outcomes

  1. Ratios of the plasma concentration at 30 minutes post-infusion to the concentrations at 10 and 15 minutes post-infusion

    Time frame: Up to 4 hours post-dose

Secondary outcomes

  1. Adverse events

    Time frame: Up to 4 hours post-dose

  2. Vital signs

    Time frame: Up to 4 hours post-dose

  3. ECG

    Time frame: Up to 4 hours post-dose

  4. Clinical laboratory blood tests

    Time frame: Up to 4 hours post-dose

Sponsors and collaborators

Lead sponsor

Norgine

Industry

Registry information

Official study title

Investigation of the Sensitivity of Different Methods to Detect NRL972 in Healthy Volunteers During and After a 2-hour Intravenous Infusion of 10 and 30mg NRL972

Important dates

Study start
2010
Primary completion
2010
Study completion
2011
First posted
Jul 16, 2010
Registry last updated
Jun 10, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.